Ranran Yang1,2,3,#, Dan Yuan2,#, Chaohan Liang4,#, Siying Zhu4, Jie Huang2, Yingqi Zhang4, Weiling He5, Qinghai Li1,*, Hong Zhang2,*
Oncology Research, Vol.33, No.12, pp. 3945-3971, 2025, DOI:10.32604/or.2025.064463
- 27 November 2025
Abstract Background: Colorectal cancer (CRC) is a predominant contributor to global cancer-associated mortality worldwide. Oxaliplatin (OXP), a foundational chemotherapeutic agent for CRC, often exhibits limited efficacy due to the emergence of drug resistance. Although endothelin-1 (EDN1) has been implicated in tumor drug resistance, its role in oxaliplatin resistance in CRC remains poorly defined. This work aimed to define how EDN1 contributes to oxaliplatin resistance and to explore its potential as a therapeutic target. Methods: Public genomic datasets were analyzed to confirm EDN1 upregulation in colorectal cancer (CRC) and its association with poor prognosis. EDN1 expression was… More >